A 16-Month Community-Based Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease

被引:14
|
作者
Oldenburg, Niki C. [1 ]
Duval, Sue [2 ]
Luepker, Russell V. [2 ]
Finnegan, John R. [2 ]
LaMarre, Heather [2 ]
Peterson, Kevin A. [2 ]
Zantek, Nicole D. [2 ]
Jacobs, Ginny [2 ]
Straka, Robert J. [2 ]
Miller, Karen H. [2 ]
Hirsch, Alan T. [2 ]
机构
[1] Univ Minnesota, Sch Med, Div Cardiovasc, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Minneapolis, MN 55455 USA
来源
PREVENTING CHRONIC DISEASE | 2014年 / 11卷
关键词
LOW-DOSE ASPIRIN; CORONARY-HEART-DISEASE; EVENTS; PROGRAMS; OUTCOMES; PEOPLE; ADULTS;
D O I
10.5888/pcd11.130378
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Introduction Cardiovascular diseases are the leading causes of disability and death in the United States. Primary prevention of these events may be achieved through aspirin use. The ability of a community-based intervention to increase aspirin use has not been evaluated. The objective of this study was to evaluate an educational intervention implemented to increase aspirin use for primary prevention of cardiovascular disease in a small city in Minnesota. Methods A community-based intervention was implemented during 16 months in a medium-sized community in Minnesota. Messages for aspirin use were disseminated to individuals, health care professionals, and the general population. Independent cross-sectional samples of residents (men aged 45-79, women aged 55-79) were surveyed by telephone to identify candidates for primary prevention aspirin use, examine their characteristics, and determine regular aspirin use at baseline and after the campaign at 4 months and 16 months. Results In primary prevention candidates, regular aspirin use rates increased from 36% at baseline to 54% at 4 months (odds ratio = 2.05; 95% confidence interval, 1.09-3.88); the increase was sustained at 52% at 16 months (odds ratio = 1.89; 95% confidence interval, 1.02-3.49). The difference in aspirin use rates at 4 months and 16 months was not significant (P=.77). Conclusion Aspirin use rates for primary prevention remain low. A combined public health and primary care approach can increase and sustain primary prevention aspirin use in a community setting.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Aspirin for primary prevention of cardiovascular disease in Japan
    Morimoto, Takeshi
    Matsui, Kunihiko
    INTERNAL MEDICINE, 2007, 46 (15) : 1281 - 1281
  • [22] Aspirin for Primary Prevention of Cardiovascular Disease Events
    Nemerovski, Carrie W.
    Salinitri, Francine D.
    Morbitzer, Kathryn A.
    Moser, Lynette R.
    PHARMACOTHERAPY, 2012, 32 (11): : 1020 - 1035
  • [23] An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease
    Plazak, Michael E.
    Mouradjian, Mallory T.
    Watson, Kristin
    Reed, Brent N.
    Noel, Zachary R.
    Devabhakthuni, Sandeep
    Gale, Stormi E.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (08) : 561 - 573
  • [24] Aspirin for the Primary Prevention of Cardiovascular Disease A Review of the Literature and Considerations for Clinical Practice
    Cicci, Jonathan D.
    Iyer, Prashanth
    Clarke, Megan M.
    Mazzella, Anthony J.
    CARDIOLOGY IN REVIEW, 2020, 28 (02) : 98 - 106
  • [25] Comparison of uptake and predictors of adherence in primary and secondary prevention of cardiovascular disease in a community-based cardiovascular prevention programme (MyAction Westminster)
    Murray, Kathryn A.
    Murphy, David J.
    Clements, Sarah-Jane
    Brown, Adrian
    Connolly, Susan B.
    JOURNAL OF PUBLIC HEALTH, 2014, 36 (04) : 644 - 650
  • [26] Aspirin for primary prevention of cardiovascular disease: Advice for a decisional strategy based on risk stratification
    Aimo, Alberto
    De Caterina, Raffaele
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2020, 23 (02) : 70 - 78
  • [27] Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease
    Michaud, Tzeyu L.
    Abraham, Jean
    Jalal, Hawre
    Luepker, Russell V.
    Duval, Sue
    Hirsch, Alan T.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (12):
  • [28] Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews
    Sutcliffe, P.
    Connock, M.
    Gurung, T.
    Freeman, K.
    Johnson, S.
    Kandala, N-B
    Grove, A.
    Gurung, B.
    Morrow, S.
    Clarke, A.
    HEALTH TECHNOLOGY ASSESSMENT, 2013, 17 (43) : 1 - +
  • [29] Change Page Don't use aspirin for primary prevention of cardiovascular disease
    Barnett, Helen
    Burrill, Peter
    Iheanacho, Ike
    BRITISH MEDICAL JOURNAL, 2010, 340
  • [30] Underutilization of Aspirin for Primary Prevention of Cardiovascular Disease Among HIV-Infected Patients
    Burkholder, Greer A.
    Tamhane, Ashutosh R.
    Salinas, Jorge L.
    Mugavero, Michael J.
    Raper, James L.
    Westfall, Andrew O.
    Saag, Michael S.
    Willig, James H.
    CLINICAL INFECTIOUS DISEASES, 2012, 55 (11) : 1550 - 1557